Objective To evaluate the effectiveness of recombinant human growth hormone(rhGH) for growth hormone deficiency(GHD)with the relative risk of neoplasms,cancer mortality and the second neoplasms. Methods The research study about the application of recombinant human growth hormone in treating GHD and cancer-related literature searched in Pubmed,EMbase,The CNKI,CBM,the Cochrane Library and so on.According to the Cochrane Handbook,literature was screened,methodological quality assessed,date extrated and meta-analysis conducted using Revman 5.3 software. Results A total of 16 research references were including,the results of meta-analysis showed that the risk of neoplasms in GHD patients treated with rhGH was not higher (RR=0.76,95%CI was 0.59~0.90,P<0.05).Application of rhGH treatment,the overall mean neoplasms standardized mortality ratios(SMR) for treated patients was not significantly increased,and that rhGH did not increase mortality in patients with cancer(SMR=0.90,95%CI was 0.77~1.05,P>0.05).But for patients who previously suffered from cancer,after the application of rhGH,which could further increase neoplasms risk 1.3 times (RR=2.30,95%CI was 1.61~3.27,P<0.05). Conclution The relative risk and the SMR of neoplasms in GHD patients treated with rhGH is not higher,but the second neoplasms risk increases by about 1.3 times.
Key words
recombinant human growth hormone /
safety /
the relative risk of neoplasms /
systematic review
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] 袁意,杨玉.特发性矮小基因研究进展[J].南昌大学学报,2013,53(1):104-106.
[2] Arnold JR,Arnold DF,Marland A,et al.GH replacement in patients with non-functioning pituitary adenoma (NFA) treated solely by surgery is not associated with increased risk of tumour recurrence[J].Clinical Endocrinology,2009,70(3):435-438.
[3] Buchfelder M,Kann PH,Wuster C,et al.Influence of GH substitution therapy in deficient adults on the recurrence rate of hormonally inactive pituitary adenomas:a case control study[J].European journal of endocrinology / European Federation of Endocrine Societies,2007,157(2):149-156.
[4] Child CJ,Zimmermann AG,Woodmansee WW,et al.Assessment of primary cancers in GH-treated adult hypopituitary patients:an analysis from the hypopituitary control and complications study[J].European Journal of Endocrinology / European Federation of Endocrine Societies,2011,165(2):217-223.
[5] Hartman ML,Xu R,Crowe BJ,et al.Prospective safety surveillance of GH-deficient adults:comparison of GH-treated vs untreated patients[J].The Journal of Clinical Endocrinology and Metabolism,2013,98(3):980-988.
[6] Hatrick AG,Boghal P,Bingham JB,et al.Does GH replacement therapy in adult GH-deficient patients result in recurrence or increase in size of pituitary tumours?[J].European Journal of endocrinology / European Federation of Endocrine Societies,2002,146(6):807-811.
[7] Mackenzie S,Craven T,Gattamaneni HR,et al.Long-term safety of growth hormone replacement after CNS irradiation[J].The Journal of Clinical Endocrinology and Metabolism,2011,96(9):2756-2761.
[8] Olsson DS,Buchfelder M,Schlaffer S,et al.Comparing progression of non-functioning pituitary adenomas in hypopituitarism patients with and without long-term GH replacement therapy[J].European Journal of Endocrinology / European Federation of Endocrine Societies,2009,161(5):663-669.
[9] Olsson DS,Buchfelder M,Wiendieck K,et al.Tumour recurrence and enlargement in patients with craniopharyngioma with and without GH replacement therapy during more than 10 years of follow-up[J].European Journal of Endocrinology/European Federation of Endocrine Societies,2012,166(6):1061-1068.
PDF(601 KB)
